Metal chelator decreases Alzheimer beta-amyloid plaques
Related Experiment Video
Updated: Oct 5, 2026

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
1Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY 10021, USA.
Abstract:
Transgenic mice developing beta-amyloid (Abeta) plaques are advancing experimental treatment strategies for Alzheimer's disease. The metal chelator, clioquinol, is reported by Cherny et al. (2001) to reduce Abeta plaques, presumably by chelation of Abeta-associated zinc and copper. This and other recent Abeta-modulating treatment approaches are discussed.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer Disease l: Introduction
Antiprotozoal Agents

